GC
AGRX

Grimes & Company’s Agile Therapeutics AGRX Stock Holding History

Grimes & Company’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56
Closed -$23K – 308
2022
Q1 		$23K Buy
56
+14
+33% +$8.94K ﹤0.01% 299
2021
Q4 		$41K Sell
42
-8
-16% -$11.3K ﹤0.01% 297
2021
Q3 		$96K Buy
50
+5
+11% +$11.3K ﹤0.01% 295
2021
Q2 		$121K Buy
45
+19
+73% +$62.6K 0.01% 294
2021
Q1 		$107K Buy
26
+11
+73% +$59.5K 0.01% 272
2020
Q4 		$86K Hold
15
– – ﹤0.01% 260
2020
Q3 		$89K Buy
15
+4
+36% +$22.9K 0.01% 243
2020
Q2 		$59K Buy
11
+1
+10% +$5.2K ﹤0.01% 242
2020
Q1 		$37K Hold
10
– – ﹤0.01% 225
2019
Q4 		$50K Buy
+10
New +$34.9K ﹤0.01% 263

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Grimes & Company's AGRX Position: Q2 2022 in Review

Grimes & Company sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 56 shares — an estimated $23K sold.

Grimes & Company first reported a position in AGRX in Q4 2019 and held it in 10 quarters. The position peaked at $121K in Q2 2021. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • Grimes & Company reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Grimes & Company sold 56 Agile Therapeutics shares in Q2 2022, an estimated $23K.
  • Grimes & Company first reported a position in Agile Therapeutics in Q4 2019 and held it in 10 quarters.
  • Grimes & Company's Agile Therapeutics position peaked at $121K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Grimes & Company's 13F filing for Q2 2022, filed 22 Jul 2022.